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The American obstetrician, Joseph DeLee, ‘father of modern obstetrics’, founded the Chicago 
Lying-in Hospital in 1931 with his vision for womens’ health captured in a set of five stone 
plaques at the top of the cloister of the hospital’s building. Four of the five stone plaques are 
engraved with the names of pioneering clinicians whose contributions to the field of obstetrics and 
gynaecology have been seminal: Jan Palfyn (1650-1730), for introducing the obstetric forceps in 
the 1720s, Hendrik Van Deventer (1651-1724), for discovering obstetric anatomical disorders, 
William Smellie (1697-1763), for improving the design of the forceps, and Eduardo Porro (1842 –
1902), for introducing hysterectomy to stop postpartum haemorrhage. The fifth stone plaque, in 
the centre, which is still blank today, is reserved for the physician/scientist who discovers the 
cause and cure of preeclampsia according to legend.
That clusters of preeclamsia occur in family units prompted the question whether preecclampsia is 
an inherited disorder, and if so, what is the mode of inheritance? Familial clustering opened the A
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possibility of deploying genome wide association studies (GWAS) for the identification of 
candidate genes and susceptibility loci for the development of preeclampsia and researchers have 
focused on this question since the discovery of DNA. However, till date, there has been no clearly 
defined causal relationship between a preeclampsia genotype and phenotype except for 
heterozygous women who are pregnant with long-chain hydroxyacyl-CoA dehydrogenase 
deficient fetus who have nearly 80% chance of developing HELLP syndrome or acute fatty liver 
of pregnancy. Defining the genetics and mode of inheritance of preeclampsia is challenged in part 
by the involvement of two genomes (maternal and fetal), and a wide spectrum of women who 
meet the diagnostic criteria according to the International Society for the Study of Hypertension in 
Pregnancy. 
There is persuasive literature that coexisting maternal medical disorders such as diabetes, chronic 
hypertension, renal disease, autoimmune disease, antiphospholipid antibody syndrome and other 
maternal-fetal risk factors including obesity, dyslipidemia, nulliparity, previous/family history of 
preeclampsia, and multifetal gestation, increase the risk of preeclampsia. In this issue of the 
Journal, Gray and colleagues (BJOG 2020 xxxx) used single nucleotide polymorphisms (SNPs) 
for 21 distinct clinical traits for increased risk of preeclampsia within 7 categories (cardiovascular, 
inflammatory/ autoimmune, insulin resistance, liver, obesity, renal, and thrombophilia) from the 
European GWAS to test the hypothesis that women with genetic predisposition to these disorders 
would have increased risk of preeclampsia in a case/control sample of data from the largest known 
US preeclampsia GWAS. The authors’ findings that; a) risk alleles for raised diastolic blood 
pressure and increased BMI were strongly associated with preeclampsia risk (more so for the 
early-onset disease variant), b) risk alleles for raised alkaline phosphatase levels, increased HDL, 
GFR, and venous thromboembolism were protective, and c) no significant associations for the 
other traits examined, are consistent with the current status of preeclampsia and HELLP as highly 
complex disorders with variable clinical presentations depending on pre-pregnancy maternal 
conditions, fetal/placental genotypes, and maternal adaptation to the challenge of pregnancy. 
So, preeclampsia is far from a Mendelian inherited type of genetic disease and the search for its 
cause and cure continues 90 years after DeLee’s vision! 
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